GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASEP Medical Holdings Inc (OTCPK:SEPSF) » Definitions » COGS-to-Revenue

ASEP Medical Holdings (ASEP Medical Holdings) COGS-to-Revenue : 0.09 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is ASEP Medical Holdings COGS-to-Revenue?

ASEP Medical Holdings's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was $0.06 Mil.

ASEP Medical Holdings's COGS to Revenue for the three months ended in Mar. 2024 was 0.09.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. ASEP Medical Holdings's Gross Margin % for the three months ended in Mar. 2024 was 90.91%.


ASEP Medical Holdings COGS-to-Revenue Historical Data

The historical data trend for ASEP Medical Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASEP Medical Holdings COGS-to-Revenue Chart

ASEP Medical Holdings Annual Data
Trend Dec21 Dec22 Dec23
COGS-to-Revenue
- - 6.31

ASEP Medical Holdings Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 3.56 0.09

ASEP Medical Holdings COGS-to-Revenue Calculation

ASEP Medical Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.101 / 0.016
=6.31

ASEP Medical Holdings's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.005 / 0.055
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ASEP Medical Holdings  (OTCPK:SEPSF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

ASEP Medical Holdings's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.005 / 0.055
=90.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


ASEP Medical Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of ASEP Medical Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


ASEP Medical Holdings (ASEP Medical Holdings) Business Description

Traded in Other Exchanges
Address
730 View Street, Suite 420, Victoria, BC, CAN, V8W 3Y7
ASEP Medical Holdings Inc is a biotechnology firm pursuing the commercialization of broad-spectrum peptide technology. The Company is dedicated to addressing the global issue of antibiotic failure by developing novel solutions for significant unmet medical needs in human medicine and is engaged in the business of acquiring research and development assets, technology, or businesses in life sciences and medical diagnostics.